EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyse

The effect of glucagon-like peptide-1 receptor agonists on bone metabolism: A systematic review and meta-analysis of randomized placebo-controlled trials of predominantly first-generation agents

Mohammad Safargar, Navid Ahmadi, Kousalya Prabahar, Reza Zandi, Hamed Kord-Varkaneh

Bone · 2027-02 · 215 · 118160

DOI: 10.1016/j.bone.2026.118160 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bone, 2027-02. Verfasst von Mohammad Safargar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. Die Arbeit nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve cardiometabolic outcomes, but their isolated effects on human bone remodeling remain uncertain because prior syntheses pooled heterogeneous study designs and active antidiabetic comparators. This systematic review and meta-analysis quantified the effects of GLP-1RAs versus placebo on densitometric, biochemical, and inflammatory markers of bone metabolism in randomized controlled trials (RCTs). METHODS: Scopus, Web of Science, Embase, and PubMed/MEDLINE were searched from inception through May 12, 2026 for randomized placebo-controlled trials of GLP-1RAs or dual incretin agonists administered for 12 to 52 weeks. Eleven trials provided compatible data for random-effects meta-analysis and one additional trial was synthesized narratively, comprising 11 trials of first-generation agents (exenatide, dulaglutide, liraglutide) and one trial of second-generation semaglutide (1.0 mg/week), with zero eligible placebo-controlled trials identified for semaglutide 2.4 mg/week or tirzepatide. Weighted mean differences (WMDs) with 95% confidence intervals (CIs) were calculated for dual-energy X-ray absorptiometry (DXA) bone mineral density (BMD), bone turnover markers, and high-sensitivity C-reactive protein (hs-CRP), and evidence certainty was rated using GRADE. RESULTS: Compared with placebo, GLP-1RA treatment reduced lumbar spine BMD (WMD: -0.02 g/cm2, 95% CI: -0.03 to -0.00, I2 = 0.0%; 3 trials, N = 222; Moderate certainty) and increased the bone resorption marker C-terminal telopeptide (CTX) (WMD: 0.05 μg/L, 95% CI: 0.01 to 0.08, I2 = 72.5%; 6 trials, N = 439; Low certainty), while reducing serum hs-CRP (WMD: -0.49 mg/L, 95% CI: -0.97 to -0.00, I2 = 0.0%; 4 trials [5 arms], N = 340; Low certainty). No significant differences were observed for femoral neck BMD (WMD: 0.01 g/cm2, 95% CI: -0.02 to 0.04, I2 = 68.9%; 5 trials [6 arms], N = 323; Very Low certainty), total hip BMD (WMD: 0.00 g/cm2, 95% CI: -0.02 to 0.03, I2 = 70.8%; 5 trials [6 arms], N = 382; Low certainty), or procollagen type 1 N-terminal propeptide (P1NP) (WMD: -1.24 μg/L, 95% CI: -3.61 to 1.13, I2 = 0.0%; 5 trials, N = 399; Moderate certainty), and leave-one-out exclusion of the single semaglutide trial did not alter the direction or significance of any pooled estimate. CONCLUSIONS: Treatment with predominantly first-generation GLP-1RAs over 12 to 52 weeks increases osteoclastic bone resorption and induces a small, borderline reduction in lumbar spine BMD while preserving hip BMD and lowering systemic inflammation. Because existing placebo-controlled RCTs largely reflect earlier-generation agents with moderate weight loss, these findings cannot be extrapolated to higher-potency anti-obesity therapies such as semaglutide 2.4 mg/week or tirzepatide, which require dedicated long-term skeletal safety trials.

Schlagwörter

Stichwörter der Autor:innen

Bone metabolismBone mineral densityBone resorptionGLP-1 receptor agonistsMeta-analysisSystematic review

Autor:innen und Institutionen

  • Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Urology and nephrology research center (UNRC), Research Institute for Urology and Nephrology, Shahid Labbafinejad Hospital, Shahid Beheshti University of Medical, Sciences (SBMU), Tehran, Iran.
  • Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
  • Musculoskeletal Injuries Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: reza.zandi.md@gmail.com.
  • Urology and nephrology research center (UNRC), Research Institute for Urology and Nephrology, Shahid Labbafinejad Hospital, Shahid Beheshti University of Medical, Sciences (SBMU), Tehran, Iran. Electronic address: hamed…

Zitieren

APA

Safargar, M., Ahmadi, N., Prabahar, K., Zandi, R., & Kord-Varkaneh, H. (2027). The effect of glucagon-like peptide-1 receptor agonists on bone metabolism: A systematic review and meta-analysis of randomized placebo-controlled trials of predominantly first-generation agents. Bone, 215, 118160. https://doi.org/10.1016/j.bone.2026.118160

Vancouver

Safargar M, Ahmadi N, Prabahar K, Zandi R, Kord-Varkaneh H. The effect of glucagon-like peptide-1 receptor agonists on bone metabolism: A systematic review and meta-analysis of randomized placebo-controlled trials of predominantly first-generation agents. Bone. 2027;215:118160. doi:10.1016/j.bone.2026.118160

BibTeX
@article{Safargar2027,
  author = {Safargar, Mohammad and Ahmadi, Navid and Prabahar, Kousalya and Zandi, Reza and Kord-Varkaneh, Hamed},
  title = {The effect of glucagon-like peptide-1 receptor agonists on bone metabolism: A systematic review and meta-analysis of randomized placebo-controlled trials of predominantly first-generation agents},
  journal = {Bone},
  year = {2027},
  volume = {215},
  pages = {118160},
  doi = {10.1016/j.bone.2026.118160}
}
Kostenlos starten →